4.02
Xeris Biopharma Holdings Inc stock is traded at $4.02, with a volume of 1.65M.
It is down -2.19% in the last 24 hours and down -30.81% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$4.11
Open:
$4.04
24h Volume:
1.65M
Relative Volume:
0.59
Market Cap:
$640.39M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-9.5714
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
-3.37%
1M Performance:
-30.81%
6M Performance:
+32.67%
1Y Performance:
+131.03%
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XERS
Xeris Biopharma Holdings Inc
|
4.02 | 640.39M | 181.41M | -59.56M | -38.83M | -0.42 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Mar-28-24 | Initiated | Oppenheimer | Outperform |
Aug-28-23 | Initiated | Craig Hallum | Buy |
Oct-21-22 | Initiated | Jefferies | Buy |
Apr-28-22 | Initiated | Craig Hallum | Buy |
Nov-17-21 | Initiated | SVB Leerink | Outperform |
Oct-29-21 | Initiated | H.C. Wainwright | Buy |
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Feb-18-20 | Initiated | Piper Sandler | Overweight |
Jul-16-18 | Initiated | Jefferies | Buy |
Jul-16-18 | Initiated | Leerink Partners | Outperform |
Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
JPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Alliancebernstein L.P. Reduces Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short Interest - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc. - Defense World
Raymond James Financial Inc. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Wellington Management Group LLP Sells 6,532 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Purchased by Prudential Financial Inc. - Defense World
AIGH Capital Management LLC Purchases 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi - openPR
Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks
Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com South Africa
Xeris Announces Changes To Its Board Of Directors - MarketScreener
Xeris Biopharma reshuffles board, appoints new director - Investing.com
Xeris Announces Changes to Its Board of Directors - Business Wire
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World
Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com India
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa
Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business
Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph
12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace
Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St
Xeris BiopharmaPossibly the best Pharma Stock - MSN
Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World
Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews
Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider
What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey
Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):